CD40 and neoplasm: In conclusion, we have generated bispecific agonist CD40/FAP DARPin® molecules able to activate the CD40 pathway in cellular assays in a targeting-dependent manner, supporting the hypothesis that these DARPin® molecules could lead to a tumor-localized immune activation in vivo.